SG10201607926VA - Forms of rifaximin and uses thereof - Google Patents
Forms of rifaximin and uses thereofInfo
- Publication number
- SG10201607926VA SG10201607926VA SG10201607926VA SG10201607926VA SG10201607926VA SG 10201607926V A SG10201607926V A SG 10201607926VA SG 10201607926V A SG10201607926V A SG 10201607926VA SG 10201607926V A SG10201607926V A SG 10201607926VA SG 10201607926V A SG10201607926V A SG 10201607926VA
- Authority
- SG
- Singapore
- Prior art keywords
- rifaximin
- forms
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/16—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3132908P | 2008-02-25 | 2008-02-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201607926VA true SG10201607926VA (en) | 2016-11-29 |
Family
ID=41016698
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201607926VA SG10201607926VA (en) | 2008-02-25 | 2009-02-25 | Forms of rifaximin and uses thereof |
SG2013021837A SG188931A1 (en) | 2008-02-25 | 2009-02-25 | Forms of rifaximin and uses thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2013021837A SG188931A1 (en) | 2008-02-25 | 2009-02-25 | Forms of rifaximin and uses thereof |
Country Status (21)
Country | Link |
---|---|
US (7) | US8067429B2 (zh) |
EP (1) | EP2257557A4 (zh) |
JP (2) | JP5706693B2 (zh) |
KR (1) | KR101674382B1 (zh) |
CN (2) | CN102015725B (zh) |
AU (1) | AU2009219342B2 (zh) |
BR (1) | BRPI0908864A2 (zh) |
CA (1) | CA2716830C (zh) |
CR (2) | CR11657A (zh) |
EA (2) | EA201370208A1 (zh) |
GE (1) | GEP20135898B (zh) |
IL (1) | IL207730A (zh) |
MA (1) | MA32161B1 (zh) |
ME (1) | ME01032B (zh) |
MX (2) | MX344737B (zh) |
MY (1) | MY158257A (zh) |
NZ (1) | NZ587099A (zh) |
SG (2) | SG10201607926VA (zh) |
UA (2) | UA113275C2 (zh) |
WO (1) | WO2009108730A2 (zh) |
ZA (2) | ZA201005961B (zh) |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7923553B2 (en) | 2003-11-07 | 2011-04-12 | Alfa Wassermann, S.P.A. | Processes for the production of polymorphic forms of rifaximin |
US7902206B2 (en) | 2003-11-07 | 2011-03-08 | Alfa Wassermann, S.P.A. | Polymorphic forms α, β and γ of rifaximin |
ITMI20032144A1 (it) | 2003-11-07 | 2005-05-08 | Alfa Wassermann Spa | Forme polimorfe di rifaximina, processi per ottenerle e |
US7906542B2 (en) | 2004-11-04 | 2011-03-15 | Alfa Wassermann, S.P.A. | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
SI1698630T1 (sl) | 2005-03-03 | 2015-01-30 | Alfa Wassermann S.P.A. | Nove polimorfne oblike rifaksimina, postopki za njihovo pripravo in njihova uporaba v medicinskih pripravkih |
US8486956B2 (en) * | 2008-02-25 | 2013-07-16 | Salix Pharmaceuticals, Ltd | Forms of rifaximin and uses thereof |
ME01032B (me) | 2008-02-25 | 2012-10-20 | Salix Pharmaceuticals Ltd | FORME RIFAKSIMINA l NJIHOVA UPOTREBA |
US11779571B2 (en) | 2008-02-26 | 2023-10-10 | Salix Pharmaceuticals, Inc. | Methods for treating irritable bowel syndrome (IBS) |
US20110035232A1 (en) | 2008-10-02 | 2011-02-10 | Salix Pharmaceuticals, Ltd. | Methods of treating hepatic encephalopathy |
US7928115B2 (en) | 2008-10-02 | 2011-04-19 | Salix Pharmaceuticals, Ltd. | Methods of treating travelers diarrhea and hepatic encephalopathy |
HUE065491T2 (hu) | 2008-10-02 | 2024-05-28 | Salix Pharmaceuticals Ltd | A hepatikus enkefalopátia kezelése rifaximin alkalmazásával |
US9018684B2 (en) | 2009-11-23 | 2015-04-28 | California Institute Of Technology | Chemical sensing and/or measuring devices and methods |
IT1399141B1 (it) * | 2010-04-02 | 2013-04-05 | Secci | Metodo per la preparazione di rifaximina in stato amorfo. |
IT1397107B1 (it) * | 2009-12-28 | 2012-12-28 | Lavagna | Nuovo metodo per la preparazione di antibiotici in stato amorfo e prodotti ottenuti utilizzando detto metodo. |
WO2011080691A1 (en) | 2009-12-28 | 2011-07-07 | Silvio Massimo Lavagna | Method for the production of amorphous rifaximin |
IT1398550B1 (it) * | 2010-03-05 | 2013-03-01 | Alfa Wassermann Spa | Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo |
AU2015203018B2 (en) * | 2010-06-03 | 2016-10-20 | Salix Pharmaceuticals, Ltd. | New forms of rifaximin and uses thereof |
CN103269587A (zh) * | 2010-06-03 | 2013-08-28 | 萨利克斯药品有限公司 | 利福昔明的新形式及其用途 |
US8883795B2 (en) * | 2010-06-16 | 2014-11-11 | Apotex Pharmachem Inc. | Polymorphic forms of Rifaximin |
CA2804635C (en) * | 2010-07-12 | 2019-09-10 | Salix Pharmaceuticals, Ltd. | Formulations of rifaximin and uses thereof |
WO2012035544A2 (en) * | 2010-09-13 | 2012-03-22 | Sequent Scientific Ltd. | A novel polymorphic form of rifaximin and process for its preparation |
IT1403847B1 (it) | 2010-09-22 | 2013-11-08 | Alfa Wassermann Spa | Composizioni farmaceutiche comprendenti rifaximina e loro uso. |
AU2012214239B2 (en) * | 2011-02-11 | 2016-06-30 | Salix Pharmaceuticals, Ltd. | Forms of Rifaximin and uses thereof |
CA2834829A1 (en) * | 2011-05-02 | 2012-11-08 | Ranbaxy Laboratories Limited | Rifaximin dimethylformamide solvate |
WO2012155981A1 (en) | 2011-05-19 | 2012-11-22 | Friulchem Spa | New process for the synthesis of rifaximin and a new pseudo-crystalline form of rifaximin obtained thereby |
ITMI20110890A1 (it) * | 2011-05-19 | 2012-11-20 | A M S A Anonima Materie Sint & Affini S P A | Polimorfo di rifaximina e processo per la sua preparazione |
ITMI20110983A1 (it) * | 2011-05-30 | 2012-12-01 | A M S A Anonima Materie Sint & Affini S P A | Amorfo di rifaximina e processo per la sua preparazione |
WO2013027227A1 (en) * | 2011-07-20 | 2013-02-28 | Ind-Swift Laboratories Limited | Novel polymorphic form i of rifaximin |
ITBO20110461A1 (it) | 2011-07-29 | 2013-01-30 | Alfa Wassermann Spa | Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali. |
WO2013067394A1 (en) | 2011-11-02 | 2013-05-10 | Salix Pharmaceuticals, Ltd | Methods for treating irritable bowel syndrome (ibs) and infections |
WO2013112809A2 (en) * | 2012-01-25 | 2013-08-01 | Salix Pharmaceuticals, Ltd | Rifaximin derivative and uses thereof |
JP2013184902A (ja) * | 2012-03-06 | 2013-09-19 | Aska Pharmaceutical Co Ltd | リファキシミン含有結晶 |
CA2876737A1 (en) * | 2012-06-13 | 2013-12-19 | Apotex Pharmachem Inc. | Polymorphic forms of rifaximin |
ITBO20120368A1 (it) * | 2012-07-06 | 2014-01-07 | Alfa Wassermann Spa | Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso. |
WO2014091432A1 (en) * | 2012-12-12 | 2014-06-19 | Ranbaxy Laboratories Limited | Pharmaceutical compositions of rifaximin |
JP2016516988A (ja) | 2013-03-15 | 2016-06-09 | アルファ ワッセルマン ソシエタ ペル アチオニAlfa Wassermann S.P.A. | 膣感染症を診断するための方法 |
US20160038468A1 (en) | 2013-03-15 | 2016-02-11 | Alfa Wassermann S.P.A. | Rifaximin for use in the treating of vaginal infections |
AU2014252219B2 (en) | 2013-04-12 | 2018-11-22 | Alfasigma S.P.A. | NSAID administration and related compositions, methods and systems. |
ITMI20131307A1 (it) | 2013-08-02 | 2015-02-02 | A M S A Anonima Materie Sint & Affini S P A | Processo per la preparazione di refaximina k |
CN103509038B (zh) * | 2013-09-30 | 2016-01-20 | 浙江思贤制药有限公司 | 一种新晶型利福昔明ζ及其制备方法 |
EP2927235B1 (en) * | 2014-03-31 | 2017-02-08 | Euticals S.P.A. | Polymorphic mixture of rifaximin and its use for the preparation of solid formulations |
WO2015171493A1 (en) | 2014-05-04 | 2015-11-12 | Salix Pharmaceuticals, Inc. | Ibs microbiota and uses thereof |
RS59250B1 (sr) | 2014-05-12 | 2019-10-31 | Alfasigma Spa | Novi solvatni kristalni oblik rifaksimina, njegova proizvodnja, kompozicije i upotreba |
CN106999477B (zh) * | 2014-06-30 | 2020-04-10 | 萨利克斯药品公司 | 用于重复治疗肠易激综合征(ibs)的方法 |
US9988398B2 (en) | 2016-06-07 | 2018-06-05 | Cadila Healthcare Limited | Crystalline form of rifaximin and process for its preparation |
WO2018064472A1 (en) | 2016-09-30 | 2018-04-05 | Salix Pharmaceuticals, Ltd. | Solid dispersion forms of rifaximin |
CN106632396B (zh) * | 2017-01-06 | 2019-01-11 | 成都樵枫科技发展有限公司 | γ晶型利福昔明的制备方法和用途 |
US10143656B1 (en) | 2017-08-04 | 2018-12-04 | Braintree Laboratories, Inc. | Solid oral sulfate salt formulations for cleaning a colon and methods of using same |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1154655B (it) * | 1980-05-22 | 1987-01-21 | Alfa Farmaceutici Spa | Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica |
IT1199374B (it) * | 1984-05-15 | 1988-12-30 | Alfa Farmaceutici Spa | Processo per la preparazione di pirido-imidazo-rifamicine |
WO2001051919A2 (en) * | 2000-01-07 | 2001-07-19 | Transform Pharmaceuticals, Inc. | High-throughput formation, identification, and analysis of diverse solid-forms |
US20080262024A1 (en) * | 2003-11-07 | 2008-10-23 | Giuseppe Claudio Viscomi | Rifaximin compositions and method of use |
US7906542B2 (en) | 2004-11-04 | 2011-03-15 | Alfa Wassermann, S.P.A. | Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin |
ITMI20032144A1 (it) | 2003-11-07 | 2005-05-08 | Alfa Wassermann Spa | Forme polimorfe di rifaximina, processi per ottenerle e |
US7902206B2 (en) | 2003-11-07 | 2011-03-08 | Alfa Wassermann, S.P.A. | Polymorphic forms α, β and γ of rifaximin |
US7923553B2 (en) | 2003-11-07 | 2011-04-12 | Alfa Wassermann, S.P.A. | Processes for the production of polymorphic forms of rifaximin |
DE602005013671D1 (de) | 2004-07-22 | 2009-05-14 | Cumbre Pharmaceuticals Inc | (r/s) rifamycin-derivate, ihre herstellung und pharmazeutische zusammensetzungen |
US8003118B2 (en) | 2005-03-02 | 2011-08-23 | Kodsi Robert E | Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis |
SI1698630T1 (sl) | 2005-03-03 | 2015-01-30 | Alfa Wassermann S.P.A. | Nove polimorfne oblike rifaksimina, postopki za njihovo pripravo in njihova uporaba v medicinskih pripravkih |
ITBO20050123A1 (it) | 2005-03-07 | 2005-06-06 | Alfa Wassermann Spa | Formulazioni farmaceutiche gastroresistenti contenenti rifaximina |
EP2069363B1 (en) | 2006-09-22 | 2013-03-20 | Cipla Ltd. | Rifaximin in an amorphous form |
US20100136125A1 (en) | 2006-12-28 | 2010-06-03 | Jacobus Pharmaceutical Company, Inc. | Method of treating inflammatory bowel disease |
ITMI20071241A1 (it) | 2007-06-20 | 2008-12-21 | Solmag S P A | Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta |
US8383151B2 (en) | 2007-07-06 | 2013-02-26 | Lupin Limited | Pharmaceutical compositions of rifaximin |
US7709634B2 (en) | 2007-09-20 | 2010-05-04 | Apotex Pharmachem Inc. | Amorphous form of rifaximin and processes for its preparation |
WO2009047801A1 (en) | 2007-10-10 | 2009-04-16 | Lupin Limited | Therapeutic combinations and compositions for the treatment of gastrointestinal disorders |
US8486956B2 (en) | 2008-02-25 | 2013-07-16 | Salix Pharmaceuticals, Ltd | Forms of rifaximin and uses thereof |
ME01032B (me) | 2008-02-25 | 2012-10-20 | Salix Pharmaceuticals Ltd | FORME RIFAKSIMINA l NJIHOVA UPOTREBA |
US20090324736A1 (en) * | 2008-05-07 | 2009-12-31 | Salix Pharmaceuticals, Ltd. | Methods of treating bowel diseases by administering a bowel cleanser and an antibiotic |
ES2855426T3 (es) | 2008-09-17 | 2021-09-23 | Mylan Inc | Granulados, proceso de preparación de los mismos y productos farmacéuticos que los contienen |
KR20110107806A (ko) | 2008-12-10 | 2011-10-04 | 시플라 리미티드 | 리팍시민 복합체 |
KR102456997B1 (ko) | 2009-10-27 | 2022-10-19 | 루핀 리미티드 | 리팍시민의 고형 분산물 |
WO2011080691A1 (en) * | 2009-12-28 | 2011-07-07 | Silvio Massimo Lavagna | Method for the production of amorphous rifaximin |
CN103269587A (zh) | 2010-06-03 | 2013-08-28 | 萨利克斯药品有限公司 | 利福昔明的新形式及其用途 |
US8883795B2 (en) | 2010-06-16 | 2014-11-11 | Apotex Pharmachem Inc. | Polymorphic forms of Rifaximin |
AU2012214239B2 (en) | 2011-02-11 | 2016-06-30 | Salix Pharmaceuticals, Ltd. | Forms of Rifaximin and uses thereof |
-
2009
- 2009-02-25 ME MEP-2010-132A patent/ME01032B/me unknown
- 2009-02-25 SG SG10201607926VA patent/SG10201607926VA/en unknown
- 2009-02-25 CN CN200980115558.1A patent/CN102015725B/zh not_active Expired - Fee Related
- 2009-02-25 CA CA2716830A patent/CA2716830C/en active Active
- 2009-02-25 CN CN201410468373.1A patent/CN104650114A/zh active Pending
- 2009-02-25 EA EA201370208A patent/EA201370208A1/ru unknown
- 2009-02-25 BR BRPI0908864A patent/BRPI0908864A2/pt not_active IP Right Cessation
- 2009-02-25 UA UAA201214275A patent/UA113275C2/uk unknown
- 2009-02-25 US US12/393,012 patent/US8067429B2/en active Active
- 2009-02-25 MX MX2012006275A patent/MX344737B/es unknown
- 2009-02-25 AU AU2009219342A patent/AU2009219342B2/en not_active Ceased
- 2009-02-25 MX MX2010009389A patent/MX2010009389A/es active IP Right Grant
- 2009-02-25 MY MYPI2010003692A patent/MY158257A/en unknown
- 2009-02-25 WO PCT/US2009/035192 patent/WO2009108730A2/en active Application Filing
- 2009-02-25 UA UAA201011414A patent/UA101829C2/uk unknown
- 2009-02-25 EA EA201001372A patent/EA021176B1/ru not_active IP Right Cessation
- 2009-02-25 GE GEAP200911948A patent/GEP20135898B/en unknown
- 2009-02-25 JP JP2010547866A patent/JP5706693B2/ja not_active Expired - Fee Related
- 2009-02-25 KR KR1020107021366A patent/KR101674382B1/ko active IP Right Grant
- 2009-02-25 SG SG2013021837A patent/SG188931A1/en unknown
- 2009-02-25 EP EP09713956A patent/EP2257557A4/en not_active Withdrawn
- 2009-02-25 NZ NZ587099A patent/NZ587099A/xx not_active IP Right Cessation
-
2010
- 2010-08-19 IL IL207730A patent/IL207730A/en not_active IP Right Cessation
- 2010-08-20 ZA ZA2010/05961A patent/ZA201005961B/en unknown
- 2010-08-25 US US12/868,322 patent/US20110105550A1/en not_active Abandoned
- 2010-08-27 CR CR11657A patent/CR11657A/es unknown
- 2010-09-13 MA MA33179A patent/MA32161B1/fr unknown
-
2011
- 2011-09-06 US US13/226,053 patent/US20120076857A1/en not_active Abandoned
-
2012
- 2012-08-23 US US13/593,453 patent/US8754098B2/en active Active
- 2012-10-03 US US13/644,241 patent/US9181274B2/en active Active
-
2013
- 2013-11-13 ZA ZA2013/08527A patent/ZA201308527B/en unknown
-
2014
- 2014-12-23 US US14/580,458 patent/US9359357B2/en active Active
-
2015
- 2015-02-27 JP JP2015038078A patent/JP2015129168A/ja active Pending
- 2015-08-04 CR CR20150401A patent/CR20150401A/es unknown
-
2016
- 2016-04-28 US US15/141,099 patent/US9700545B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201308527B (en) | Forms of rifaximin and uses thereof | |
HRP20180718T1 (hr) | Oligopeptidni spojevi i njihova upotreba | |
HK1179608A1 (zh) | 利福昔明的晶型及其用途 | |
HK1172896A1 (zh) | 化合物和使用方法 | |
HK1161094A1 (zh) | 化合物和使用方法 | |
IL210804A (en) | Benzylidenehydrazides and their uses | |
IL211042A (en) | The history of imidazopyridine-2-on and its uses | |
HK1149933A1 (zh) | 二氮咔唑和其使用方法 | |
ZA201102604B (en) | Alkylcyclohexylethers of dihydrotetraazabenzoazulenes | |
IL209548A0 (en) | Diazacarbazoles and methods of use | |
PL2133419T3 (pl) | Zastosowania beta-dipeptydów cyjanoficyny | |
ZA201103456B (en) | Leukolectins and uses thereof | |
EP2291377A4 (en) | IMIDAZOPYRIMIDINONE AND ITS USES | |
HK1160925A1 (zh) | 組織蛋白酶 的用途 | |
PL2247601T3 (pl) | Tiazopirymidynony i ich zastosowanie | |
IL206951A0 (en) | 3-alkyl-piperazine derivatives and uses thereof | |
GB0705204D0 (en) | Uses of (S)-clenbuterol | |
GB0808857D0 (en) | Methdos and uses | |
IL206950A0 (en) | Aminopiperidinyl derivatives and uses thereof |